

Review Form 1.6

Journal Name:	Journal of Pharmaceutical Research International
Manuscript Number:	Ms_JPRI_77862
Title of the Manuscript:	EVALUATION OF ANTICANCER EFFECT OF LIPPIA NODIFLORA LEAF EXTRACT ON LUNG CANCER
Type of the Article	

General guideline for Peer Review process:

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty**', provided the manuscript is scientifically robust and technically sound. To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

(<http://peerreviewcentral.com/page/manuscript-withdrawal-policy>)

Review Form 1.6

PART 1: Review Comments

	Reviewer's comment	Author's comment (if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)
<p>Compulsory REVISION comments</p>	<ol style="list-style-type: none"> 1- In the materials and methods part, the name of the MTT product must be written as follows: 3- (4,5-dimethylthiazol-2-yl) -2,5-diphenyl tetrazolium bromide. 3-(4,5-dimethylthiazol-2-yl) 2,5-diphenyl tetrazolium bromide (MTT) 2- In the results section, the author has oddly cited the name of another different plant (Saraca asoca) instead of Lippia nodiflora. This must be corrected. The cells were treated with different concentrations (10-120 µg/ml) of Saraca asoca flower extract for 24h. Saraca asoca flower extract treatment significantly decreased the viability of A-549 cancer cells compared to control at 24 h time point (Figure-1) 3- In the commentary to Figure 1, the author spoke of the different concentrations of the plant extract with which the A549 cell lines were treated, he writes 200µg / ml instead of 120µg / ml. The cells were treated with different concentrations (10, 20, 40, 80, 100 and 200 µg/ml) of Lippia nodiflora leaf extract for 24 hrs 4- In the discussion part the author referring to reference 18 said: The hematological parameters showed no significant alteration which led to the increase in the catalase and superoxide dismutase, decreased glutathione and lipid peroxidation, showed that presence of antitumor activity of the methanol extract of the plant which could be exhibited due to presence of antioxidant components (18). while reading this above-mentioned article I did not find this information On the contrary, I saw that our plant was never mentioned there I suggest it's up to the writer to drop this paragraph or show us how he quoted it. 5- Flavonoids are found to play the most important role in the Lippia nodiflora leaf extract of the plant and that causes the apoptosis(27) (28) (29) (30) (31) (32) (33) (34) (35) (36) (37) (38) (39) (40) (41) In this paragraph, you must limit to 2 or 3 references, especially if not yet cited, references from 30 to 41 are only mentioned to complete the list of references. 6- Thus, as a result, Lippia nodiflora leaf extract will be a safer medicine for treating lung cancer as it does not produce any side effects. Our studies are part of the preclinical phase so it cannot conclude on the safety of the plant extract, this is the field of phase I studies. 7- The second reference is not well written. A systematic review on cancer therapy in ayurveda. 2018 [cited 2020 Jun 2]; Available from: https://www.semanticscholar.org/paper/4826402a2fe9968a5aa082b955b2ddb22e514952 	
<p>Minor REVISION comments</p>		
<p>Optional/General comments</p>		

Review Form 1.6

PART 2:

	Reviewer's comment	Author's comment <i>(if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)</i>
Are there ethical issues in this manuscript?	<i>(If yes, Kindly please write down the ethical issues here in details)</i>	

Reviewer Details:

Name:	Chighaly El Hadj Sidi
Department, University & Country	National Center of Cardiology, Mauritania